COMPARATIVE ANALYSIS OF THE ANTICANCER ACTIVITY OF ANGIOTENSIN RECEPTOR BLOCKERS - IRBESARTAN AND TELMISARTAN
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i12.27948Keywords:
Methylthiazolyldiphenyl-tetrazoliumbromide assay, Irbesartan, Telmisartan, Cytotoxicity, Angiotensin receptor blockersAbstract
Objective: Angiotensin receptor blockers (ARBs) are effective hypertensive drugs. Reduction in risk of lung cancer with ARBs was proven in clinical studies. Telmisartan and irbesartan are the second-generation ARBs. This study screens the anticancer activity of these two drugs in a dose-dependent manner using A549 cell line.
Methods: Different concentrations of irbesartan and telmisartan were treated on A549 cells and the anticancer activity was evaluated through methylthiazolyldiphenyl-tetrazolium [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cytotoxicity assay. The dot plot of the cytotoxicity results was used to extrapolate the half maximal inhibitory concentration (IC50) values. Microscopic changes in the cells post-treatment with these drugs were also recorded at ideal concentrations.
Results: A reduction in cell viability was noted in A549 cells with increasing concentration of the drug. The IC50 values for irbesartan and telmisartan were 31.1 μg and 15.6 μg, respectively. Microscopic observation of the cells shows more rounded and deformed dead cells on telmisartan- and irbesartan-treated cells when compared with the untreated control.
Conclusion: The results confirm the anticancer activity of both the drugs with telmisartan being more efficient. The anticancer activity could probably be due to the role of irbesartan and telmisartan in inhibiting mitogen-activated protein kinase cell survival pathway and local angiogenesis.
Downloads
References
Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent) 2003;16:123-6.
de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72.
Sleight P, Jakobsen A, Heroys J, Ralph A, Rees T, Shaw M, et al. No HOPE without proof: Do ARBs meet the standard for cardiovascular protection? Medscape J Med 2008;10 Suppl: S6.
Soubra L, Nureddin H, Omar A, Saleh M. Factors associated with hypertension prevalence and control among lebanese Type 2 diabetic patients. Int J Pharm Pharm Sci 2018;8:153-9.
Nakagami H, Kiomy Osako M, Nakagami F, Shimosato T, Minobe N, Moritani T, et al. Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan. Int J Mol Med 2010;26:477-81.
Jose A, Wilson D, George M, Reshma K Thomas R, Justin A. Comparative study on the beneficial effects of telmisartan and other antihypertensive agents in stroke patients. Int J Pharm Pharm Sci 2017;9:99-102.
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme. Lancet 2003;362:759-66.
Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol 2010;11:627-36.
Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. Angiotensin receptor blockers and risk of cancer: Cohort study among people receiving antihypertensive drugs in UK general practice research database. BMJ 2012;344:e2697.
Zhang J, Liu J, Chen J, Li X, Wu Y, Chen H, et al. Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: A systematic review and meta-analysis. Int J Clin Exp Med 2015;8:12656-60.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. International Agency for Research on Cancer; 2013. GLOBOCAN. Vol. 1 0. Cancer Incidence and Mortality Worldwide. Lyon, France: IARC Cancer Base; 2012.
Indian Council of Medical Research; 2013. National Cancer Registry Programme. Three Year Report of Population Based Cancer Registries; 2009-2011.
Ford DW, Koch KA, Ray DE, Selecky PA. Palliative and end-of-life care in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2013;143:e498S-e512S.
Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
Yamamoto K, Ohishi M, Ho C, Kurtz TW, Rakugi H. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009;54:1353-9.
Roovers K, Assoian RK. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 2000;22:818-26.
Rakusan K, Chvojkova Z, Oliviero P, Ostadalova I, Kolar F, Chassagne C, et al. ANG II type 1 receptor antagonist irbesartan inhibits coronary angiogenesis stimulated by chronic intermittent hypoxia in neonatal rats. Am J Physiol Heart Circ Physiol 2007;292:H1237-44.
Holmgren L, O’Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
Parangi S, O’Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A 1996;93:2002-7.
De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16 Suppl 2:S17-27.
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, et al. Anti-cancer natural products isolated from Chinese medicinal herbs. Chin Med 2011;6:27.
Ahmed SN, Das B, Chakraborty J. Prospective and retrospective animal model used in the pharmacological screening of anti-cancer drug. Int J Curr Pharm Res 2018;10:13-8.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
